Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc.
FUJIFILM Corporation today announced that the company has appointed Lars Petersen as the new President and Chief Executive Officer (CEO) of FUJIFILM Diosynth Biotechnologies.
The Public Investment Fund (PIF) today announced the establishment of the Pharmaceutical Investment Company (Lifera), a commercial-scale contract development and manufacturing organisation.
In this MedTalk Podcast episode, Ian Bolland is joined by Lorna Green from LYVA Labs to discuss the latest innovations in pharmaceutical manufacturing, the role of regional investment and accelerator programs, and the challenges faced by life scienc
MGC Pharmaceuticals' Malta facility has received formal EU-Good Manufacturing Practice (GMP) certification, enabling the production of high-quality plant-inspired medicines such as CannEpil and CimetrA. The large-scale facility can produce over 20
EntityRisk announced that Jeffrey B. Kindler and Frank D’Amelio have led a Series A investment in the company and have been appointed to EntityRisk’s board of directors.
Prof. Andy Whiting, Nevrargenics, responds to the lack of translational funding for the biotech industry, and what more needs to be done to close the gap between drug development and clinical trials.
Last Thursday, chancellor Jeremy Hunt announced new measures for smoother medicine approvals in the UK, increased support for R&D, and a simplified tax system for SMEs. UK biotech company, Nevrargenics shared its position on the 2023 Budget.
